By: Catherine Shu
Dr Shu discusses updated data from the VISION trial of tepotinib in patients with non–small cell lung cancer harboring MET exon 14 skipping mutations.


Catherine Shu is the Head of Content at [Employer]. She covers a range of topics including oncology, immunotherapy, hematology, and remote healthcare, with a focus on startups in Asia and breaking news. Her work has been featured in prominent outlets such as Yahoo News, Business Insider, and TechCrunch.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston


Not enough data
This information evolves through artificial intelligence and human feedback. Improve this profile .